Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

In 2023, global sales of RSV vaccines reached USD 2.46 billion, and according to industry consultants, the market size is expected to grow to approximately USD 16.7 billion by 2030.

NHS England announced on Monday that more than one million adults in England, aged between 75 and 79, or those who turned 80 after September 1, will be invited to receive the RSV jab over the next ...

NHS England has appealed for 1.3 million eligible people to come forward for a new jab against respiratory syncytial virus (RSV) which can lead to serious complications in some. It is sending ...

More than one million people in England have been urged to get vaccines for respiratory syncytial virus (RSV), with health officials warning that the virus is ‘not just a winter illness’.

More than one million Brits are being urged to get a potentially "life-saving" new jab against respiratory syncytial virus (RSV). NHS officials have urgently invited elderly people in England to ...

Invites are being sent this week to people not yet vaccinated against RSV who are aged 75-79 or turned 80 after 1 September 2024, encouraging them to book an appointment with their GP. RSV spreads all ...

The global respiratory diagnostics market, valued at US$ 5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$ 6.17 billion in 2024 and an impressive US$ 9.02 billion by ...

The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...